Elixiron Immunotherapeutics Inc.
1 known investors
Find your way into Elixiron Immunotherapeutics Inc.
Sign up to see every warm intro you have to Elixiron Immunotherapeutics Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Elixiron Immunotherapeutics Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Elixiron Immunotherapeutics develops precision immunotherapies for neuroinflammation, autoimmune diseases, and cancer, with two clinical-stage candidates: EI-1071 (Enrupatinib) for Alzheimer's, ALS, and Parkinson's, and EI-001 (Indemakitug) for vitiligo and alopecia areata. The company operates in the biotech and immunotherapy sector.
Investors · 1
Frequently asked questions
- What does Elixiron Immunotherapeutics Inc. do?
- Elixiron Immunotherapeutics develops precision immunotherapies for neuroinflammation, autoimmune diseases, and cancer, with two clinical-stage candidates: EI-1071 (Enrupatinib) for Alzheimer's, ALS, and Parkinson's, and EI-001 (Indemakitug) for vitiligo and alopecia areata. The company operates in the biotech and immunotherapy sector.
- Who are Elixiron Immunotherapeutics Inc.'s investors?
- Elixiron Immunotherapeutics Inc.'s investors include Axil Capital.
